A carregar...
Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer
BACKGROUND: Castration resistant prostate cancer (CRPC) is a leading cause of cancer-related deaths in men. The primary cause of mortality and morbidity in patients is bone metastases and remodeling resulting in osteoblastic and osteolytic lesions. Recently, cabozantinib, a multi-kinase inhibitor (V...
Na minha lista:
| Main Authors: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4190397/ https://ncbi.nlm.nih.gov/pubmed/25277255 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-742 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|